0
     

Report Added
Report already added
Biologics and Biosimilars-China Market Status and Trend Report 2015-2026

Biologics and Biosimilars-China Market Status and Trend Report 2015-2026

Report Summary

Biologics and Biosimilars-China Market Status and Trend Report 2015-2026 offers a comprehensive analysis on Biologics and Biosimilars industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole China and Regional Market Size of Biologics and Biosimilars 2015-2019, and development forecast 2020-2026
Main market players of Biologics and Biosimilars in China, with company and product introduction, position in the Biologics and Biosimilars market
Market status and development trend of Biologics and Biosimilars by types and applications
Cost and profit status of Biologics and Biosimilars, and marketing status
Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Biologics and Biosimilars market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the Biologics and Biosimilars industry.

The report segments the China Biologics and Biosimilars market as:

China Biologics and Biosimilars Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2015-2026):
North China
Northeast China
East China
Central & South China
Southwest China
Northwest China

China Biologics and Biosimilars Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2015-2026):
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others

China Biologics and Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2015-2026; Downstream Customers and Market Analysis)
Tumor
Diabetes
Cardiovascular
Hemophilia
Others

China Biologics and Biosimilars Market: Players Segment Analysis (Company and Product introduction, Biologics and Biosimilars Sales Volume, Revenue, Price and Gross Margin):
Roche
Eli Lilly
Sanofi-Aventis
Amgen
Novo Nordisk
AbbVie
Merck
Pfizer
Johnson & Johnson
Novartis
Gelgen
Ganlee
3sbio
Innovent
Biotech
Changchun High Tech
Dong Bao
CP Guojian

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Table of Contents
Chapter 1 Overview of Biologics and Biosimilars
1.1 Definition of Biologics and Biosimilars in This Report
1.2 Commercial Types of Biologics and Biosimilars
1.2.1 Monoclonal Antibodies
1.2.2 Interferon
1.2.3 Erythropoietin
1.2.4 Insulin
1.2.5 Vaccines
1.2.6 Others
1.3 Downstream Application of Biologics and Biosimilars
1.3.1 Tumor
1.3.2 Diabetes
1.3.3 Cardiovascular
1.3.4 Hemophilia
1.3.5 Others
1.4 Development History of Biologics and Biosimilars
1.5 Market Status and Trend of Biologics and Biosimilars 2015-2026
1.5.1 China Biologics and Biosimilars Market Status and Trend 2015-2026
1.5.2 Regional Biologics and Biosimilars Market Status and Trend 2015-2026
Chapter 2 China Market Status and Forecast by Regions
2.1 Market Status of Biologics and Biosimilars in China 2015-2019
2.2 Consumption Market of Biologics and Biosimilars in China by Regions
2.2.1 Consumption Volume of Biologics and Biosimilars in China by Regions
2.2.2 Revenue of Biologics and Biosimilars in China by Regions
2.3 Market Analysis of Biologics and Biosimilars in China by Regions
2.3.1 Market Analysis of Biologics and Biosimilars in North China 2015-2019
2.3.2 Market Analysis of Biologics and Biosimilars in Northeast China 2015-2019
2.3.3 Market Analysis of Biologics and Biosimilars in East China 2015-2019
2.3.4 Market Analysis of Biologics and Biosimilars in Central & South China 2015-2019
2.3.5 Market Analysis of Biologics and Biosimilars in Southwest China 2015-2019
2.3.6 Market Analysis of Biologics and Biosimilars in Northwest China 2015-2019
2.4 Market Development Forecast of Biologics and Biosimilars in China 2020-2026
2.4.1 Market Development Forecast of Biologics and Biosimilars in China 2020-2026
2.4.2 Market Development Forecast of Biologics and Biosimilars by Regions 2020-2026
Chapter 3 China Market Status and Forecast by Types
3.1 Whole China Market Status by Types
3.1.1 Consumption Volume of Biologics and Biosimilars in China by Types
3.1.2 Revenue of Biologics and Biosimilars in China by Types
3.2 China Market Status by Types in Major Countries
3.2.1 Market Status by Types in North China
3.2.2 Market Status by Types in Northeast China
3.2.3 Market Status by Types in East China
3.2.4 Market Status by Types in Central & South China
3.2.5 Market Status by Types in Southwest China
3.2.6 Market Status by Types in Northwest China
3.3 Market Forecast of Biologics and Biosimilars in China by Types
Chapter 4 China Market Status and Forecast by Downstream Industry
4.1 Demand Volume of Biologics and Biosimilars in China by Downstream Industry
4.2 Demand Volume of Biologics and Biosimilars by Downstream Industry in Major Countries
4.2.1 Demand Volume of Biologics and Biosimilars by Downstream Industry in North China
4.2.2 Demand Volume of Biologics and Biosimilars by Downstream Industry in Northeast China
4.2.3 Demand Volume of Biologics and Biosimilars by Downstream Industry in East China
4.2.4 Demand Volume of Biologics and Biosimilars by Downstream Industry in Central & South China
4.2.5 Demand Volume of Biologics and Biosimilars by Downstream Industry in Southwest China
4.2.6 Demand Volume of Biologics and Biosimilars by Downstream Industry in Northwest China
4.3 Market Forecast of Biologics and Biosimilars in China by Downstream Industry
Chapter 5 Market Driving Factor Analysis of Biologics and Biosimilars
5.1 China Economy Situation and Trend Overview
5.2 Biologics and Biosimilars Downstream Industry Situation and Trend Overview
Chapter 6 Biologics and Biosimilars Market Competition Status by Major Players in China
6.1 Sales Volume of Biologics and Biosimilars in China by Major Players
6.2 Revenue of Biologics and Biosimilars in China by Major Players
6.3 Basic Information of Biologics and Biosimilars by Major Players
6.3.1 Headquarters Location and Established Time of Biologics and Biosimilars Major Players
6.3.2 Employees and Revenue Level of Biologics and Biosimilars Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
Chapter 7 Biologics and Biosimilars Major Manufacturers Introduction and Market Data
7.1 Roche
7.1.1 Company profile
7.1.2 Representative Biologics and Biosimilars Product
7.1.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Roche
7.2 Eli Lilly
7.2.1 Company profile
7.2.2 Representative Biologics and Biosimilars Product
7.2.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly
7.3 Sanofi-Aventis
7.3.1 Company profile
7.3.2 Representative Biologics and Biosimilars Product
7.3.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
7.4 Amgen
7.4.1 Company profile
7.4.2 Representative Biologics and Biosimilars Product
7.4.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Amgen
7.5 Novo Nordisk
7.5.1 Company profile
7.5.2 Representative Biologics and Biosimilars Product
7.5.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.6 AbbVie
7.6.1 Company profile
7.6.2 Representative Biologics and Biosimilars Product
7.6.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie
7.7 Merck
7.7.1 Company profile
7.7.2 Representative Biologics and Biosimilars Product
7.7.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Merck
7.8 Pfizer
7.8.1 Company profile
7.8.2 Representative Biologics and Biosimilars Product
7.8.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer
7.9 Johnson & Johnson
7.9.1 Company profile
7.9.2 Representative Biologics and Biosimilars Product
7.9.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.10 Novartis
7.10.1 Company profile
7.10.2 Representative Biologics and Biosimilars Product
7.10.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Novartis
7.11 Gelgen
7.11.1 Company profile
7.11.2 Representative Biologics and Biosimilars Product
7.11.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Gelgen
7.12 Ganlee
7.12.1 Company profile
7.12.2 Representative Biologics and Biosimilars Product
7.12.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Ganlee
7.13 3sbio
7.13.1 Company profile
7.13.2 Representative Biologics and Biosimilars Product
7.13.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio
7.14 Innovent
7.14.1 Company profile
7.14.2 Representative Biologics and Biosimilars Product
7.14.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Innovent
7.15 Biotech
7.15.1 Company profile
7.15.2 Representative Biologics and Biosimilars Product
7.15.3 Biologics and Biosimilars Sales, Revenue, Price and Gross Margin of Biotech
7.16 Changchun High Tech
7.17 Dong Bao
7.18 CP Guojian
Chapter 8 Upstream and Downstream Market Analysis of Biologics and Biosimilars
8.1 Industry Chain of Biologics and Biosimilars
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
Chapter 9 Cost and Gross Margin Analysis of Biologics and Biosimilars
9.1 Cost Structure Analysis of Biologics and Biosimilars
9.2 Raw Materials Cost Analysis of Biologics and Biosimilars
9.3 Labor Cost Analysis of Biologics and Biosimilars
9.4 Manufacturing Expenses Analysis of Biologics and Biosimilars
Chapter 10 Marketing Status Analysis of Biologics and Biosimilars
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
Chapter 11 Report Conclusion
Chapter 12 Research Methodology and Reference
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference

Report Title: Biologics and Biosimilars-China Market Status and Trend Report 2015-2026


Your Details
Valid Invalid number
Roche
Eli Lilly
Sanofi-Aventis
Amgen
Novo Nordisk
AbbVie
Merck
Pfizer
Johnson & Johnson
Novartis
Gelgen
Ganlee
3sbio
Innovent
Biotech
Changchun High Tech
Dong Bao
CP Guojian

SELECT A FORMAT

ADD TO CART BUY NOW